PubMed=3740860
Miyao Y., Shimizu K., Okamoto Y., Matsui Y., Ushio Y., Yoshida T., Hayakawa T., Tsuda N., Mogami H.
Meningeal gliomatosis model in nude mice.
Gan To Kagaku Ryoho 13:2600-2605(1986)

PubMed=3496051
Yamada M., Shimizu K., Okamoto Y., Miyao Y., Matsui Y., Tsuda N., Mogami H.
Experimental studies on the treatment of recurrent gliomas.
Gan To Kagaku Ryoho 14:1890-1895(1987)

PubMed=2504489
Tamura K., Shimizu K., Yamada M., Okamoto Y., Matsui Y., Park K.C., Mabuchi E., Moriuchi S., Mogami H.
Expression of major histocompatibility complex on human medulloblastoma cells with neuronal differentiation.
Cancer Res. 49:5380-5384(1989)

DOI=10.1016/B978-0-12-333530-2.50005-8
Nister M., Westermark B.
Human glioma cell lines.
(In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.17-42; Academic Press; New York (1994)

PubMed=9310141; DOI=10.1111/j.1349-7006.1997.tb00436.x
Miyao Y., Shimizu K., Tamura M., Akita H., Ikeda K., Mabuchi E., Kishima H., Hayakawa T., Ikenaka K.
Usefulness of a mouse myelin basic protein promoter for gene therapy of malignant glioma: myelin basic protein promoter is strongly active in human malignant glioma cells.
Jpn. J. Cancer Res. 88:678-686(1997)

PubMed=20587068; DOI=10.1186/1471-2407-10-339
Nakabayashi H., Yawata T., Shimizu K.
Anti-invasive and antiangiogenic effects of MMI-166 on malignant glioma cells.
BMC Cancer 10:339.1-339.9(2010)